205 related articles for article (PubMed ID: 17127711)
1. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer.
Kim CS; Ying H; Willingham MC; Cheng SY
Carcinogenesis; 2007 May; 28(5):932-9. PubMed ID: 17127711
[TBL] [Abstract][Full Text] [Related]
2. Pituitary tumor-transforming gene regulates multiple downstream angiogenic genes in thyroid cancer.
Kim DS; Franklyn JA; Stratford AL; Boelaert K; Watkinson JC; Eggo MC; McCabe CJ
J Clin Endocrinol Metab; 2006 Mar; 91(3):1119-28. PubMed ID: 16394085
[TBL] [Abstract][Full Text] [Related]
3. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
Ying H; Willingham MC; Cheng SY
Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
[TBL] [Abstract][Full Text] [Related]
4. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.
Suzuki H; Willingham MC; Cheng SY
Thyroid; 2002 Nov; 12(11):963-9. PubMed ID: 12490073
[TBL] [Abstract][Full Text] [Related]
5. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
Kato Y; Ying H; Willingham MC; Cheng SY
Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
[TBL] [Abstract][Full Text] [Related]
6. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
[TBL] [Abstract][Full Text] [Related]
7. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
Kim CS; Furuya F; Ying H; Kato Y; Hanover JA; Cheng SY
Endocrinology; 2007 Mar; 148(3):1306-12. PubMed ID: 17170101
[TBL] [Abstract][Full Text] [Related]
8. Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.
Furuya F; Ying H; Zhao L; Cheng SY
Steroids; 2007 Feb; 72(2):171-9. PubMed ID: 17169389
[TBL] [Abstract][Full Text] [Related]
9. Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
Kim DS; Franklyn JA; Boelaert K; Eggo MC; Watkinson JC; McCabe CJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4603-11. PubMed ID: 16926250
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer.
Boelaert K; McCabe CJ; Tannahill LA; Gittoes NJ; Holder RL; Watkinson JC; Bradwell AR; Sheppard MC; Franklyn JA
J Clin Endocrinol Metab; 2003 May; 88(5):2341-7. PubMed ID: 12727994
[TBL] [Abstract][Full Text] [Related]
12. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
13. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors.
McCabe CJ; Boelaert K; Tannahill LA; Heaney AP; Stratford AL; Khaira JS; Hussain S; Sheppard MC; Franklyn JA; Gittoes NJ
J Clin Endocrinol Metab; 2002 Sep; 87(9):4238-44. PubMed ID: 12213878
[TBL] [Abstract][Full Text] [Related]
15. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Guigon CJ; Cheng SY
Mol Cell Endocrinol; 2009 Sep; 308(1-2):63-9. PubMed ID: 19549593
[TBL] [Abstract][Full Text] [Related]
16. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.
Ying H; Suzuki H; Furumoto H; Walker R; Meltzer P; Willingham MC; Cheng SY
Carcinogenesis; 2003 Sep; 24(9):1467-79. PubMed ID: 12869418
[TBL] [Abstract][Full Text] [Related]
17. Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice.
Zimonjic DB; Kato Y; Ying H; Popescu NC; Cheng SY
Cancer Genet Cytogenet; 2005 Sep; 161(2):104-9. PubMed ID: 16102579
[TBL] [Abstract][Full Text] [Related]
18. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
Suzuki H; Zhang XY; Forrest D; Willingham MC; Cheng SY
Mol Endocrinol; 2003 May; 17(5):895-907. PubMed ID: 12576488
[TBL] [Abstract][Full Text] [Related]
19. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
[TBL] [Abstract][Full Text] [Related]
20. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression.
Ying H; Furuya F; Zhao L; Araki O; West BL; Hanover JA; Willingham MC; Cheng SY
J Clin Invest; 2006 Nov; 116(11):2972-84. PubMed ID: 17039256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
